Department of Dermatology, AP-HP, Henri Mondor University Hospital, Université Paris-Est Créteil (UPEC), Créteil, France; Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379, Université Paris-Est Créteil (UPEC), Créteil, France.
Health Economics and Outcomes Research Strategy Team, AbbVie, North Chicago, Illinois, USA.
J Invest Dermatol. 2024 Mar;144(3):540-546.e1. doi: 10.1016/j.jid.2023.08.025. Epub 2023 Sep 20.
Patients with vitiligo incur direct and indirect costs associated with their condition; however, data regarding the economic burden of vitiligo are scarce and outdated. In this retrospective cohort analysis of the Merative MarketScan Commercial Database, healthcare costs and healthcare resource utilization (HCRU) were evaluated among United States patients with vitiligo. Patients with vitiligo were matched (1:2) with individuals without vitiligo (controls) between January 2007 and December 2021. Outcomes included all-cause and vitiligo-related costs (2021 dollars) and all-cause HCRU, including mental health-related HCRU, during a 1-year postindex period. Subgroup analyses were completed for patients on vitiligo treatments with systemic effects (such as phototherapy and oral steroids) or a new mental health diagnosis. The analysis was focused solely on direct costs. Baseline demographics were well-balanced between matched vitiligo (49,512) and control (99,024) cohorts. Patients with vitiligo incurred significantly higher all-cause ($15,551 vs $7735) and vitiligo-related ($3490 vs $54) costs than controls (P < .0001). All-cause and mental health-related HCRU were also significantly higher among patients with vitiligo (P < .0001). Differences in all-cause and vitiligo-related healthcare costs remained significantly higher in patients on treatments with systemic effects/mental health diagnoses than in controls (P < .0001). Taken together, healthcare costs and HCRU were significantly higher among patients with vitiligo than among controls.
白癜风患者会产生与其病情相关的直接和间接费用；然而，有关白癜风经济负担的数据稀缺且已过时。在对 Merative MarketScan 商业数据库的这项回顾性队列分析中，评估了美国白癜风患者的医疗保健费用和医疗保健资源利用（HCRU）。2007 年 1 月至 2021 年 12 月期间，将白癜风患者（病例组）与无白癜风患者（对照组）按 1:2 进行匹配。结果包括病例组和对照组在索引后 1 年内的全因和白癜风相关费用（2021 年美元）以及全因 HCRU，包括心理健康相关 HCRU。对接受具有全身作用（如光疗和口服类固醇）的白癜风治疗或新的心理健康诊断的患者进行了亚组分析。分析仅关注直接成本。匹配的白癜风（49512 例）和对照组（99024 例）队列的基线人口统计学特征均衡良好。与对照组相比，白癜风患者的全因费用（15551 美元比 7735 美元）和白癜风相关费用（3490 美元比 54 美元）显著更高（P<.0001）。白癜风患者的全因和心理健康相关 HCRU 也显著更高（P<.0001）。与对照组相比，接受全身作用/心理健康诊断治疗的患者的全因和白癜风相关医疗费用差异仍显著更高（P<.0001）。总之，与对照组相比，白癜风患者的医疗保健费用和 HCRU 显著更高。
